Cybin to present at the jefferies inaugural biotech cns/neuro summit

Toronto--(business wire)--cybin inc. (nyse american:cybn) (neo:cybn) (“cybin” or the “company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that doug drysdale, cybin's chief executive officer, will present at the jefferies inaugural biotech cns/neuro summit, taking place october 11-12, 2023 in new york city, ny. mr. drysdale's presentation will be webcast l.
CYBN Ratings Summary
CYBN Quant Ranking